Back to UBS Group AG UBS Group AG

SCNISCNI
Showing 8 of 9 quarters

Position history for UBS Group AGUBS Group AG's holdings in SCINAI IMMUNOTHERAPEUTICS LT

UBS Group AG holds 3,955 shares of SCNI (SCINAI IMMUNOTHERAPEUTICS LT), worth $1,001 as of 2026-Q2. The position was increased (+330.4% shares).

Current Value

$1,001

Current Shares

3,955

Total Value Change

+$897

Total Shares Change

+3,925

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
3,955
+330.4%
$1,0010.0%$0.25
12
2026-Q1
Decreased
919
-47.4%
$5240.0%$0.80
0
2025-Q4
Increased
1,748
+218x
$1,2450.0%$0.72
12
2025-Q3
Decreased
8
-99.9%
$100.0%$1.20
0
2025-Q2
Decreased
12,056
-19.3%
$27,4880.0%$2.28
0
2025-Q1
Decreased
14,932
-36.4%
$40,2270.0%$2.80
0
2024-Q4
Increased
23,488
+782x
$78,5670.0%$3.36
23
2024-Q3
Decreased
30
-85.8%
$1040.0%$3.64
0

Other major holders of SCNI: CITADEL ADVISORS LLC, BANK OF MONTREAL /CAN/, XTX Topco Ltd

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used